Deep Dive: Independent Evidence Review Affirms Flu, RSV, and COVID Protection for Infants and Children — October 2026

Deep Dive — 18 October 2026

An independent evidence review released this week by the Vaccine Integrity Project and the American Medical Association reaffirms that influenza, RSV, and COVID-19 immunizations continue to protect infants and children from severe disease, hospitalization, and death. The review arrives while federal advisory processes remain disrupted and flu activity is rising earlier than usual in parts of the country.

Background

Respiratory viruses remain a leading cause of infant and child hospitalization each fall and winter. For years, annual influenza vaccination, maternal and infant RSV protection (via Abrysvo vaccine in pregnancy or nirsevimab monoclonal antibody), and COVID-19 vaccination have been core tools. In 2025, the CDC’s Advisory Committee on Immunization Practices (ACIP) membership was dismissed and replaced; a court challenge later succeeded, but an independent expert-led process has not fully resumed. Medical societies including the AAP have continued issuing their own schedules.

What changed this week

The Vaccine Integrity Project and AMA completed a review that screened nearly 19,000 studies published since August 2025. Key findings for pediatric practice:

No new pediatric safety signals were identified across the three immunizations in the reviewed data. The review helped inform the 2026–27 respiratory virus recommendations issued jointly by the AAP and other societies.

Competing viewpoints

Supporters of independent medical-society guidance emphasize that the evidence remains consistent with prior research and that families need clear, evidence-based recommendations while federal processes are unsettled. Critics of the current federal approach have pointed to the ACIP disruption and lower public trust as reasons families may delay or decline immunization. Some commentators argue that real-world uptake of maternal RSV vaccine has been lower than hoped in several countries, limiting population impact even when the product is effective. Others note that post-marketing safety data often lack control groups, so rare signals can be harder to quantify. Public health officials and pediatricians generally stress that the tools remain among the strongest available for preventing severe outcomes in the youngest children.

What to watch next

This summary draws on the Vaccine Integrity Project/AMA review as reported by Contemporary Pediatrics and related coverage. It is for informational purposes only and is not a substitute for individualized medical advice. Discuss timing and product choices with your clinician.